Trial Profile
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 May 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; NEO-PV 01 (Primary) ; Nivolumab (Primary) ; Poly ICLC (Primary) ; Sotigalimab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors BioNTech; Neon Therapeutics
- 01 Sep 2020 Status changed from active, no longer recruiting to discontinued.
- 27 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 20 Nov 2019 According to a Neon Therapeutics media release, the company plans to cease future enrollment in its NT-003 trial in metastatic melanoma.